Cart is empty The Biden administration is flexing some federal muscle in its push for lower drug prices, warning pharmaceutical companies that it might use its authority to cancel patent protections if a medication costs too much.
The Biden administration is flexing some federal muscle in its push for lower drug prices, warning pharmaceutical companies that it might use its authority to cancel patent protections if a medication costs too much.
Leave A Comment